Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an inactivated rabies vaccine for human use developed and marketed by Shenzhen Mellow Hope Pharmaceutical Industrial Co., Ltd. The vaccine is produced by inoculating Vero cells with the fixed rabies virus strain CTN-1V, which is then inactivated and freeze-dried into a powder for injection. It works by inducing protective neutralizing antibody responses against rabies virus antigens, providing active immunization for both pre-exposure and post-exposure prophylaxis against rabies infection. The vaccine is typically administered in 0.5 ml doses and has established a significant international presence, having been registered and marketed in countries such as Chile, India, Indonesia, the Philippines, and Thailand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine, human (Shenzhen Mellow Hope).